Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Background and Aims: Liver biopsy is the reference standard for NAFLD diagnosis and staging. NAFLD can be assessed less invasively using immunoassays to detect serum biomarkers. However, biomarkers can degrade due to sample storage conditions and therefore may not be detected using these antibody-based assays. Detection of biomarkers by mass spectrometry (MS) overcomes this disadvantage. Methods: MS and two dimensional gel electrophoresis (2DE) were used to find differences in the abundance of proteins among serum samples from patients with varying NAFLD and fibrosis stages (NAFL, NASH F0, NASH F1, NASH F3 and healthy individuals). The identified proteins are potential NAFLD biomarkers. Mass spectrometry was used to assay for biomarkers by detecting their tryptic peptides and fragments. We are the first and only lab to use a novel quantitation method with clinical samples. Unlike current liver disease biomarker tests, our approach is the only biomarker assay using a universal calibration mix. Results: Using MS and 2DE, we identified several potential biomarkers for NAFLD which were checked by both targeted MS and Western blotting using serum from patients with varying stages of NAFLD. Our novel biomarkers look promising when compared to cytokeratin-18 and the protein markers used in NashTest. A mass spectrometry assay was developed for the most promising novel liver fibrosis biomarkers. Conclusions: We are working towards the first ever antibody-free biomarker assay for NAFLD. Our assay is nine times faster than conventional quantitation by MS making our approach for absolute biomarker quantitation applicable for clinical use. In all current liver disease biomarker assays, different calibrations curves are required for each biomarker with each point on the curves being read separately and samples could be analysed several hours after establishing a calibration curve by which time there is the possibility of instrument drift. Our assay overcomes these disadvantages since it is the only assay which can analyse all points of the calibration curve and determine the absolute concentration of the NAFLD biomarker in a single acquisition. Our assay may help reduce the need for invasive liver biopsies in NAFLD patients.

Original publication

DOI

10.1159/000478719

Type

Conference paper

Publisher

Karger

Publication Date

12/07/2017

Volume

2

Pages

11 - 12

Total pages

2